Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells $537,326.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 4,600 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $116.81, for a total transaction of $537,326.00. Following the completion of the sale, the director now owns 4,600 shares of the company’s stock, valued at approximately $537,326. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

NASDAQ UTHR opened at $120.33 on Friday. United Therapeutics Co. has a 52-week low of $74.31 and a 52-week high of $127.79. The company has a 50-day simple moving average of $119.18 and a 200 day simple moving average of $102.43. The company has a debt-to-equity ratio of 0.27, a quick ratio of 8.46 and a current ratio of 8.91. The company has a market capitalization of $5.31 billion, a PE ratio of 10.04 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.43 by $0.69. United Therapeutics had a net margin of 36.59% and a return on equity of 19.19%. The business had revenue of $356.30 million during the quarter, compared to the consensus estimate of $343.68 million. During the same quarter last year, the company posted $3.58 earnings per share. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. As a group, analysts forecast that United Therapeutics Co. will post 10.4 EPS for the current fiscal year.

UTHR has been the subject of several analyst reports. Wedbush reiterated a “buy” rating and issued a $243.00 target price on shares of United Therapeutics in a report on Thursday, June 25th. Zacks Investment Research upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 target price for the company in a report on Sunday, May 3rd. Credit Suisse Group increased their target price on shares of United Therapeutics from $129.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. HC Wainwright increased their target price on shares of United Therapeutics from $85.00 to $125.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. Finally, TheStreet upgraded shares of United Therapeutics from a “c” rating to a “b” rating in a report on Wednesday, April 29th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $137.00.

Large investors have recently modified their holdings of the business. Altshuler Shaham Ltd bought a new position in United Therapeutics during the first quarter worth about $28,000. Chevy Chase Trust Holdings Inc. bought a new position in United Therapeutics during the fourth quarter worth about $31,000. NWK Group Inc. bought a new position in United Therapeutics during the fourth quarter worth about $35,000. First Mercantile Trust Co. bought a new position in United Therapeutics during the first quarter worth about $72,000. Finally, Advisor Group Holdings Inc. bought a new position in United Therapeutics during the first quarter worth about $108,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What is channel trading?

Insider Buying and Selling by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.